M.D., Ph.D., Assistant Professor of Medicine (Oncology); Stanford Cancer Institute. Dr. Kohrt investigated novel therapeutic strategies to enhance anti-tumor immunity, including the discovery of checkpoint inhibitors and cancer vaccine strategies. Dr. Kohrt was the co-director of the Cancer Immunotherapy Trials Network.
As a faculty member at Stanford, Dr. Kohrt was developing novel vaccine strategies which induce tumor antigen-specific immunity and improve graft-versus-tumor reactions without exacerbation of graft-versus-host disease. His studies also included efforts to identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies. Dr. Kohrt was a leader in the clinical development of agents including IL-15, IL-7, anti-CTLA-4, anti-CD137, anti-PD-1, anti-PD-L1, BTK inhibitors, and HPV-targeted and WT1-targeted vaccines.